Keyphrases
Lantibiotics
100%
Clostridium Difficile Infection
100%
Mutacin 1140
100%
Pharmacological Profile
75%
Novel Antibiotics
50%
Clostridioides Difficile
50%
FaSSIF
50%
Clostridium Difficile-associated Diarrhea
50%
Staphylococcus Aureus
25%
Clinical Development
25%
Screening Assays
25%
Pharmacological Therapy
25%
EC50
25%
In Vivo Efficacy
25%
Low Toxicity
25%
Biologically Relevant
25%
Vancomycin
25%
Streptococcus Pneumoniae
25%
Infection Model
25%
Lessons Learned
25%
Pseudomonas Aeruginosa (P. aeruginosa)
25%
Vancomycin-resistant Enterococci
25%
Gram-positive Infections
25%
Resistance Development
25%
Simulated Gastric Fluid
25%
Simulated Intestinal Fluid
25%
Best Performers
25%
Metabolic Stability
25%
Novel Mechanism of Action
25%
In Vitro Cytotoxicity
25%
In Vitro Drug Sensitivity Test
25%
Efficacy in Vivo
25%
Prevent Recurrence
25%
Chemical Stability
25%
Physicochemical Profile
25%
Mycobacterium Phlei
25%
Mutagenesis Library
25%
Lanthipeptide
25%
Difficile
25%
Hamster Model
25%
Bacterial Species
25%
Small-scale Fermentation
25%
Streptococcus mutans (S. mutans)
25%
Cytotoxicity Test
25%
Micrococcus Luteus
25%
Promiscuity
25%
Novel Molecules
25%
HepG2 Cells
25%
Single Amino Acid Substitution
25%
Off-target Effects
25%
HepG2 Cancer Cells
25%
Saturation mutagenesis
25%
Pharmacology, Toxicology and Pharmaceutical Science
Lantibiotic
100%
Clostridium Difficile Infection
100%
Infection
50%
Lead Compound
50%
Peptoclostridium difficile
50%
Amino Acid
25%
Antibiotics
25%
Recurrent Disease
25%
Vancomycin-Resistant Enterococcus
25%
Staphylococcus Aureus
25%
Vancomycin
25%
Gram Positive Infection
25%
Hamster Model
25%
Mutagenesis
25%
Pseudomonas aeruginosa
25%
Streptococcus mutans
25%
Mycobacterium phlei
25%
Micrococcus luteus
25%
Cytotoxicity Assay
25%
Chemical Stability
25%
Cytotoxicity
25%
EC50
25%
Streptococcus Pneumonia
25%